Blueprint Total Liab from 2010 to 2024
| BPMC Stock | USD 97.57 0.95 0.98% |
Total Liabilities | First Reported 2013-12-31 | Previous Quarter 883.3 M | Current Value 886.5 M | Quarterly Volatility 306.2 M |
Check Blueprint Medicines financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Blueprint Medicines' main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.7 M, Interest Expense of 54.2 M or Selling General Administrative of 292.2 M, as well as many indicators such as Price To Sales Ratio of 21.28, Dividend Yield of 0.0 or PTB Ratio of 44.91. Blueprint financial statements analysis is a perfect complement when working with Blueprint Medicines Valuation or Volatility modules.
Blueprint | Total Liab |
Latest Blueprint Medicines' Total Liab Growth Pattern
Below is the plot of the Total Liab of Blueprint Medicines Corp over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. Blueprint Medicines' Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Blueprint Medicines' overall financial position and show how it may be relating to other accounts over time.
| Total Liab | 10 Years Trend |
|
Total Liab |
| Timeline |
Blueprint Total Liab Regression Statistics
| Arithmetic Mean | 256,407,137 | |
| Geometric Mean | 70,208,147 | |
| Coefficient Of Variation | 136.52 | |
| Mean Deviation | 263,240,067 | |
| Median | 91,767,000 | |
| Standard Deviation | 350,035,168 | |
| Sample Variance | 122524.6T | |
| Range | 958.9M | |
| R-Value | 0.85 | |
| Mean Square Error | 36785.8T | |
| R-Squared | 0.72 | |
| Significance | 0.000062 | |
| Slope | 66,470,419 | |
| Total Sum of Squares | 1715344.7T |
Blueprint Total Liab History
About Blueprint Medicines Financial Statements
Blueprint Medicines stakeholders use historical fundamental indicators, such as Blueprint Medicines' Total Liab, to determine how well the company is positioned to perform in the future. Although Blueprint Medicines investors may analyze each financial statement separately, they are all interrelated. For example, changes in Blueprint Medicines' assets and liabilities are reflected in the revenues and expenses on Blueprint Medicines' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Blueprint Medicines Corp. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Liabilities | 918.6 M | 964.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Blueprint Medicines Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Blueprint Medicines' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Blueprint Medicines Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Blueprint Medicines Corp Stock:Check out the analysis of Blueprint Medicines Correlation against competitors. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.09) | Revenue Per Share 6.986 | Quarterly Revenue Growth 1.266 | Return On Assets (0.15) | Return On Equity (0.50) |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.